Climb Bio, Inc. (NASDAQ: CLYM) is a Healthcare company (Biotechnology) with a market capitalization of $574M. The Maz Rating grades it against the other companies in its sector.
Climb Bio, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.78, Climb Bio, Inc. trades at 3.4x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -30.6%, return on invested capital of -29.1% and a free cash flow yield of -9.4%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 26.58. Over the past 52 weeks the share price ranged from $1.64 to $18.33, with a beta of 0.07.
Climb Bio, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 7 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.